688520 Sinocelltech Inc.
- 43.04
- -1.11-2.51%
Sinocelltech Inc. News
Sinocelltech Group Limited's (SHSE:688520) Largest Shareholder, CEO Liangzhi Xie Sees Holdings Value Fall by 3.4% Following Recent Drop
Key Insights Significant insider control over Sinocelltech Group implies vested interests in company growth 69% of the company is held by a single shareholder (Liangzhi Xie) Ownership research, co
Shenzhou Cell (688520.SH): Net profit of 74.1974 million yuan in the first quarter
On April 25, Ge Longhui (688520.SH) released its report for the first quarter of 2024. During the reporting period, it achieved operating income of 613 million yuan, an increase of 86.30% over the previous year; net profit attributable to shareholders of listed companies of 74.1974 million yuan; net profit attributable to shareholders of listed companies after deducting non-recurring profit and loss of 157 million yuan; and basic earnings per share of 0.17 yuan.
Sinocelltech Forecasts Return to Profit in Q1
Sinocelltech Group (SHA:688520) forecasts an attributable profit of between 60 million yuan and 80 million yuan in the first quarter, rebounding from a loss of 153 million yuan in the year-ago period.
Shenzhou Cell (688520.SH) made a pre-profit. The net profit for the first quarter is expected to be 60 million yuan to 80 million yuan, changing from loss to profit
Shenzhou Cell (688520.SH) announced that the company expects to become a parent company in the first quarter of 2024...
Shenzhou Cell (688520.SH) announced its 2023 annual results, with a net loss of 396 million yuan, and the loss narrowed
According to Zhitong Finance App News, Shenzhou Cell (688520.SH) released its 2023 annual report. The company's revenue was 1,887 million yuan, up 84.46% year on year; net loss attributable to shareholders of listed companies was 396 million yuan, and losses narrowed; net loss attributable to shareholders of listed companies after deducting non-recurring profit and loss was 63.685 million yuan, which narrowed; basic loss per share was 0.89 yuan/share. During the reporting period, the company's net loss attributable to shareholders of listed companies after deducting non-recurring profit and loss decreased year-on-year, mainly due to a sharp increase in revenue during the reporting period compared to the same period of the previous year.
Sinocelltech's Unit Gets Nod to Trial Tumor Drug
Sinocelltech Group's (SHA:688520) unit, China Cell Engineering, will conduct clinical trials on the SCTB14 injection after receiving approval from China's National Medical Products Administration, acc
Shenzhou Cell (688520.SH): Holding subsidiary product SCTB14 received approval notice for drug clinical trials
On April 10, Ge Longhui Cell (688520.SH) announced that Shenzhou Cell Engineering Co., Ltd., a holding subsidiary of the company, received the “Drug Clinical Trial Approval Notice” approved and issued by the State Drug Administration and agreed to conduct clinical trials for patients with advanced malignant solid tumors, the product SCTB14 injection developed independently by the company. The SCTB14 product is a bispecific antibody injection for multiple solid tumors immunotherapy developed independently by the company with the goal of differentiated competitive advantage.
Sinocelltech Group Limited's (SHSE:688520) Business Is Trailing The Industry But Its Shares Aren't
When close to half the companies in the Biotechs industry in China have price-to-sales ratios (or "P/S") below 7.1x, you may consider Sinocelltech Group Limited (SHSE:688520) as a stock to potentially
SCTB35, a subsidiary of Shenzhou Cell (688520.SH) Holdings, obtained approval notice for drug clinical trials
Shenzhou Cell (688520.SH) issued an announcement. Recently, Shenzhou Cell Engineering Co., Ltd., a holding subsidiary of the company, accepted...
Shenzhou Cell (688520.SH) achieved revenue of 1,887 billion yuan in 2023, a year-on-year increase of 84.46%
According to Zhitong Finance App News, Shenzhou Cell (688520.SH) released its 2023 annual performance report. During the reporting period, the company achieved total operating revenue of 1,887 billion yuan, an increase of 84.46% over the previous year; achieved a net loss of 396 million yuan attributable to the owners of the parent company, and a net loss of 63.6805 million yuan attributable to the owners of the parent company after deducting non-recurring profit and loss. During the reporting period, sales revenue of the company's first product, Anjiain (recombinant human coagulation factor VIII), continued to increase dramatically. After the company's first antibody drug and anti-tumor product, Anpinxi (repatumab injection), was approved for marketing in August 2022,
Shenzhou Cell (688520.SH) is forecasting a loss. The net loss is expected to be 380 million yuan to 410 million yuan in 2023, narrowing the year-on-year loss
Shenzhou Cell (688520.SH) released its 2023 annual performance forecast and is expected to operate in 2023...
Sinocelltech Gets Green Light to Trial SCTC21C Injection; Shares Up 3%
Sinocelltech Group (SHA:688520) will conduct clinical trials on the SCTC21C injection after receiving approval from China's National Medical Products Administration. The Chinese drug developer will te
Shenzhou Cell (688520.SH): SCTC21C approved to conduct clinical trials to treat CD38+ hematological malignancies
Shenzhou Cell (688520.SH) announced that recently, Shenzhou Cell Engineering Co., Ltd., a holding subsidiary of the company, received the country...
Shenzhou Cell (688520.SH): Holding subsidiary product SCTC21C received a notice of approval for drug clinical trials
On January 18, Ge Longhui Cell (688520.SH) announced that its holding subsidiary Shenzhou Cell Engineering Co., Ltd. received the “Drug Clinical Trial Approval Notice” approved and issued by the State Drug Administration and agreed to conduct clinical trials of the SCTC21C injection, a product independently developed by the company, to treat CD38+ hematological malignancies.
Shenzhou Cell (688520.SH) Holding Subsidiary Shenzhou Cell Engineering Drug Registration Application Accepted
Shenzhou Cell (688520.SH) announced that the company's holding subsidiary Shenzhou Cell Engineering Co., Ltd. (“Shenzhou Cell...
Shenzhou Cell (688520.SH) finolizumab and bevacizumab marketing applications accepted
On January 17, CDE's official website revealed that the marketing applications for Shenzhou Cell (688520.SH), phenolizumab (SCT-I10A) and bevacizumab (SCT510) were accepted. The presumed indication is the combination of the two for first-line treatment of hepatocellular carcinoma.
Subdued Growth No Barrier To Sinocelltech Group Limited's (SHSE:688520) Price
Sinocelltech Group Limited's (SHSE:688520) price-to-sales (or "P/S") ratio of 13x may look like a poor investment opportunity when you consider close to half the companies in the Biotechs industry in
Shenzhou Cell (688520.SH): According to communication with the exchange at the time of the company's IPO, the company aims to achieve break-even in 2024
Gelonghui, December 29丨Shenzhou Cell (688520.SH) Investor Relations Activity Record Form shows that according to the company's communication with the exchange during the IPO, the company's goal is to achieve break-even in 2024 (not a profit forecast or commitment). The company will continue to work hard to achieve this goal. Specific measures include increasing product sales revenue and strictly managing costs and expenses. Furthermore, in order to guarantee R&D competitiveness, the company's R&D investment will remain at a high level. It is expected that the company's subsequent profit level will change greatly or cause losses according to the level and progress of R&D investment.
Shenzhou Cell (688520.SH): The company's R&D expenses will remain at a high level in 2023
Gelonghui, December 29丨Shenzhou Cell (688520.SH) Investor Relations Activity Record Form shows that the company's R&D expenses in 2023 are still at a high level, mainly due to the following aspects: first, clinical research on the quadrivalent COVID-19 vaccine (including phase III clinical trials conducted at the beginning of the year and subsequent phase II bridging clinical studies), phase III clinical costs of the 14-valent HPV vaccine, and second, the company is also actively developing a number of pre-clinical products. In 2024, the company expects multiple products to be introduced clinically, and the share of pre-clinical R&D investment will increase accordingly. Currently, the company is still an R&D enterprise, and product development is a company
Shenzhou Cell (688520.SH): The company's CD20 monoclonal antibody product An Pingxi has now been successfully included in the 2023 national medical insurance catalogue, and the product is expected to be sold starting in 2024
Gelonghui December 29丨Shenzhou Cell (688520.SH) Investor Relations Activity Record Sheet shows that the company's CD20 monoclonal antibody product An Pingxi was launched in August 2022. It has now been successfully included in the 2023 National Health Insurance Catalogue, and the product is expected to be sold starting in 2024. An Ping hopes that clinical data is beneficial, and product safety has certain advantages. We believe there will be a broad market space after entering medical insurance. The company's biosimilar Adalimumab product Anjiarun and bevacizumab product Ambeizumab have been approved for marketing in June 2023, and the products are automatically covered by medical insurance. The company already has these two
Analysis
Price Target
No Data
